We trace how two cornerstone migraine preventives, beta blockers and antidepressants, were discovered through surprising side effects rather than migraine-first research. We also break down how they work, why they fail so often, and why a structural diagnosis can open the door to nerve blocks and decompression surgery for a specific subset of patients.
• propranolol’s path from angina drug to first FDA-approved migraine prophylaxis beta blocker
• amitriptyline’s low-dose migraine benefit and why fast relief matters biologically
• proposed beta blocker mechanisms including sympathetic tone reduction and cortical spreading depression suppression
• who benefits most from beta blockers and the practical “dual benefit” cases
• common beta blocker side effects including fatigue and vivid nightmares plus lipophilic vs hydrophilic differences
• safety limits including hypoglycemic unawareness in insulin-dependent diabetes and bronchospasm risk in asthma
• how TCAs and SNRIs change serotonin and norepinephrine signaling to raise pain thresholds
• why SSRIs often underperform for migraine prevention and what that implies about norepinephrine
• TCA anticholinergic burden, narrow therapeutic index, and overdose cardiac risk
• realistic efficacy benchmarks, the 50% responder rate, and the 8–12 week trial window
• why constant daily headache patients can be excluded from trials and what that means clinically
• peripheral nerve compression as a “hardware” problem and nerve blocks as a diagnostic test
• decompression surgery outcomes in medication-refractory patients and how it fits after first-line options